Semaglutide is back at the top of the Emerging Demand Index this week with a score of 0.86, powered by a fresh FDA approval action on the molecule and Wikipedia pageviews up 4% WoW. It's the only top-five condition this week with a regulatory catalyst attached, and the read-through is clean: weight-loss demand isn't cooling, it's restocking. Operators who throttled GLP-1 spend during the spring lull should reopen the tap.

Emerging Demand — What to Watch

  • Semaglutide — EDI 0.86. Wikipedia pageviews +4% WoW plus a new FDA approval event on the molecule. Regulatory + consumer attention stacking is the cleanest leading-indicator pattern we track.
  • Insomnia — EDI 0.84. Wikipedia pageviews +6% WoW with no offsetting news catalyst — pure consumer attention. Sleep medicine clinics should expect a measurable lift in self-referral search behavior over the next 2–3 weeks.
  • Egg Freezing — EDI 0.75. Wikipedia pageviews +10% WoW and Reddit post velocity +130% WoW — the largest community-driven signal in the index. Fertility marketers: this is your window.
  • Wegovy — EDI 0.75. Wikipedia pageviews +5% WoW, reinforcing the semaglutide-class signal above. Brand-specific attention rising in parallel with the molecule itself usually precedes a script-volume bump.
  • Obesity — EDI 0.73. Wikipedia pageviews +2% WoW but 24 new recruiting trials in the last 30 days — a structural pipeline signal more than a consumer one. Bariatrics groups should expect competitive trial recruitment in their markets.

Search Intent

Google Trends produced no breakout rising or falling conditions nationally this week, and the daily trending health feed was empty. That's a quiet coincident layer — which actually strengthens the EDI read: the leading indicators are moving before search has caught up. Expect IoT confirmation on semaglutide and egg freezing in the next 1–2 weeks.

Structural Markets

Arkansas remains the most structurally underserved state in our dataset, showing up four times in the top six gaps: hypertension at 42.5% vs 34% nationally (+8.5 pts), obesity at 38.9% vs 34.3% (+4.6), depression at 25.2% vs 21.7% (+3.4), and COPD at 9.6% vs 6.3% (+3.3). For multi-site operators, AR is a four-condition expansion thesis, not a one-off. Michigan and Ohio also flag hard on depression prevalence — 26.7% and 26.6% respectively, both roughly 5 points above national — which lines up with the EDI's elevated psychiatry pipeline (17 new depression trials, 23 new anxiety trials in 30 days).

Respiratory Watch

Respiratory pressure is releasing across the board. Influenza is falling in all 112 reporting HSAs in Texas, 84 in Georgia, 63 in Michigan, and 52 in New York. RSV is falling in 99 of 99 Texas HSAs, and COVID is falling in 43 of 43 New York HSAs. Urgent care and primary care should plan for a real volume step-down through May.

The Bottom Line

Reallocate this week: pull spend from respiratory-adjacent urgent care campaigns and push it into GLP-1 weight-loss and fertility (egg freezing in particular — the +130% Reddit velocity is the loudest community signal in the index). If you operate in Arkansas, Michigan, or Ohio, the structural prevalence gaps are wide enough to justify dedicated mental health and cardiometabolic capacity planning, not just marketing.